Loading
Aclaris Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Mehra Anand, was filed 20 Nov 2024.
Aclaris Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Aclaris Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 22 October 2026, brought 40 filings signed by 13 insiders.
Only sales appear on the open market, 1 sale in all totalling €1.2M, filed by 1 insider. Biggest ticket of the year: €1.2M, sold by Leonard Braden Michael and made public on 27 April 2026 (0.17% of market cap).
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 40 filings, this issuer sits above that mark. Looking back to 2016, when coverage begins, insiders filed 46 purchases and 117 sales. The 10-K for the year ended 31 December 2025 shows 7.8 m USD of revenue and -64.9 m USD of net income.
Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
568
Thresholds
n/a
Buy Volume
€14M
46 ops. · all time
Sell Volume
€88M
117 ops. · all time
Who traded when
BuySaleAnand Mehra1 buy
Braden Michael Leonard1 sale
Since the insiders bought
- -41.9%Entry US$4.32 · Close at T+365 US$2.51
- +27.0%Entry US$1.22 · Close at T+365 US$1.55
- +26.4%Entry US$1.44 · Close at T+365 US$1.82
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Aclaris Therapeutics, Inc. Strong Buy (bullish), based on 11 analysts. Average price target: US$10.18.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,535 of 26,246 companies
11.5
score / 100
Value17
Quality6
FCF yld-8.4%
Earn yld-12%
EV/EBITDA·
ROE-59%
Gross mgn6.9%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.81
Analyst consensus
11 analystsStrong buy
US$4.00Target US$10.18(+167%)US$16.00
Income statement
RevenueUS$7.8M
Gross profitUS$542k7% margin
EBITDA-US$73.6M-941% margin
Net income-US$64.9M-829.6% margin
Valuation
PER (forward)-4.9x
P/Book4.3x
Beta0.88
Balance sheet & cash
Market capUS$560.8M
Total debtUS$426k
Free Cash Flow-US$47.2M
Debt / Equity1%
Profitability & ownership
ROE-59.1%
ROA-29.0%
% insiders2.2%
% institutions84.0%
Last declaration on 4 August 2026
Declarations568 total
36,375 sharesCommon StockSEC:0002076327-26-000006:0
12,385 shares@ US$5.200.0080% mcap100.0% of flowCommon StockSEC:0002076327-26-000006:1
11,580 sharesCommon StockSEC:0001590102-26-000002:0
11,580 sharesCommon StockSEC:0001654773-26-000003:0
11,580 sharesCommon StockSEC:0001674278-26-000002:0
11,580 sharesCommon StockSEC:0001172252-26-000002:0
11,580 sharesCommon StockSEC:0001187159-26-000002:0
11,580 sharesCommon StockSEC:0001280044-26-000004:0
9,330 shares@ US$4.410.0043% mcap100.0% of flowCommon StockSEC:0002065269-26-000004:1
36,375 sharesCommon StockSEC:0002065269-26-000004:0
300,000 shares@ US$4.530.17% mcap31.7% of flowCommon StockSEC:0001373604-26-000034:0
677 shares@ US$2.870.5% of flowCommon StockSEC:0001957554-26-000011:1
2,375 sharesCommon StockSEC:0001957554-26-000011:0
7,500 sharesCommon StockSEC:0001781549-26-000009:1
14,750 sharesCommon StockSEC:0001781549-26-000009:2
10,686 shares@ US$3.517.1% of flowCommon StockSEC:0001781549-26-000009:3
6,449 shares@ US$3.476.2% of flowCommon StockSEC:0001957554-26-000007:1
18,611 shares@ US$3.470.8% of flowCommon StockSEC:0001604457-26-000005:1
5,937 shares@ US$3.474.0% of flowCommon StockSEC:0001781549-26-000011:1
18,675 sharesCommon StockSEC:0002045027-26-000002:0
22,025 sharesCommon StockSEC:0001957554-26-000007:0
20,875 sharesCommon StockSEC:0001781549-26-000011:0
11,250 sharesCommon StockSEC:0001781549-26-000009:0
63,475 sharesCommon StockSEC:0001604457-26-000005:0
15,980 shares@ US$2.4817.1% of flowCommon StockSEC:0001781549-26-000007:0
25 of 568 declarations
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States, with headquarters in Wayne, Pennsylvania. The company has evolved from a dermatology-focused specialty biotech into a clinical-stage developer of immuno-inflammatory therapies. For investors, ACRS is best viewed as a small-cap biotech with a high-risk/high-upside profile, where valuation is primarily driven by clinical execution, pipeline breadth, and capital discipline rather than current commercial sales. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025))
Aclaris’ core business is built around internal drug discovery and early development, with particular expertise in kinase inhibition and immune-inflammatory biology. The company highlights its proprietary KINect platform and a pipeline that spans both small molecules and biologics. It also operates Confluence Discovery Technologies, a full-service discovery and early-development CRO, which supports external research relationships and broadens the company’s scientific capabilities. This structure gives Aclaris both a pipeline engine and a research-services component, although the investment case remains overwhelmingly centered on drug development outcomes. ([aclaristx.com](https://www.aclaristx.com/overview/?utm_source=openai))
Read moreShow less
The most visible asset is ATI-052, a novel anti-TSLP/IL-4Rα bispecific antibody that the company describes as potentially first-in-class. In 2026, Aclaris reported positive interim Phase 1a results and advanced into Phase 1b proof-of-concept studies in atopic dermatitis and asthma. The company expects top-line readouts from both Phase 1b studies in the second half of 2026, and it has also signaled plans to move ATI-052 into a Phase 2b program, initially in asthma, later in 2026. These updates are important because they help validate the program’s translational potential and expand the range of possible indications. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025))
A second major program is ATI-2138, an oral dual inhibitor of ITK and JAK3. Aclaris has recently identified lichen planus as the lead indication for this asset and intends to launch a phased basket study covering the most common lichen planus subtypes, including erosive mucosal, cutaneous, and lichen planopilaris. The company argues that the opportunity in lichen planus is meaningful because there are currently no FDA-approved therapies, underscoring the unmet medical need. Aclaris is also evaluating additional inflammatory and alopecia-related indications linked to this mechanism of action. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-positive-full-top-line-first))
Competitive positioning is centered on differentiation rather than scale. Aclaris does not compete as a commercial dermatology platform with large marketed revenues; instead, it competes as a focused clinical-stage innovator aiming at under-served immune-inflammatory diseases. Its geographic footprint is primarily U.S.-based, with operations centered in Pennsylvania and select collaborations or licensing arrangements abroad. The latest corporate update reported cash, cash equivalents and marketable securities of $151.4 million at December 31, 2025 and stated that this should fund operations into the second half of 2028, excluding certain future trial costs and business development activity. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025))
Recent corporate milestones include the February 2026 year-end results release, ongoing Phase 1b enrollment for ATI-052 in both atopic dermatitis and asthma, and the company’s continued expansion of its immunology pipeline. For investors in France, Belgium, and Switzerland, Aclaris is therefore a classic NASDAQ biotech story: scientifically interesting, clinically driven, and highly sensitive to readouts, partnering decisions, and funding visibility. ([investor.aclaristx.com](https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2025))
